The phase III failure of one of Bone Therapeutics’ cell therapies puts its other one under greater pressure than ever.
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.
A partial interim trial success could give GKT831 a new lease of life in liver diseases but full data, due next year, will be watched closely.
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
BAN2401 may work better in genetically defined population, but with safety risks.
A treatment-resistant schizophrenia drug would have been a blockbuster – but Lundbeck’s high risk, high-reward strategy has not paid off.
Pfizer and Lilly appear to have sacrificed some efficacy for safety with their anti-NGF pain project, tanezumab.
Poor trial design seems to have been responsible for a phase III failure, but the company has not suffered as a result.
Arbutus Biopharma already looked second best to Arrowhead Pharmaceuticals in the race to develop a functional cure for hepatitis B. New data have made the former’s task…